|View printer-friendly version|
Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
“The FDA's acceptance of our IV SB 11285 IND will allow us to soon begin the clinical development program for our novel second-generation intravenously-administered STING agonist product candidate,” said Atif Abbas, M.D., Vice President & Head of
SB 11285 is a second-generation STING agonist immunotherapeutic agent being investigated for the treatment of selected cancers such as certain breast cancers, certain lung cancers, colo-rectal cancers and melanoma. In vitro and in vivo preclinical findings indicate that SB 11285, if approved, may be used to target a variety of tumors at various anatomic sites and has the potential to enhance the activity of other therapeutic modalities such as immune checkpoint inhibitors. Preclinical studies also indicated that SB 11285 could be administered clinically either intratumorally or intravenously.
Part 1 of the IV SB 11285 Phase 1 trial is a dose-escalation study with monotherapy followed by combination with a checkpoint inhibitor and is designed to determine a recommended Phase 2 dose. Part 2 of the trial will explore IV SB 11285 antitumor activity in combination with a checkpoint inhibitor in selected tumor types. The trial will be conducted at multiple sites in
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
McNeil, Gray & Rice
Source: Spring Bank Pharmaceuticals, Inc.